|  Help  |  About  |  Contact Us

Publication : LRRC15(+) myofibroblasts dictate the stromal setpoint to suppress tumour immunity.

First Author  Krishnamurty AT Year  2022
Journal  Nature Volume  611
Issue  7934 Pages  148-154
PubMed ID  36171287 Mgi Jnum  J:336807
Mgi Id  MGI:7408618 Doi  10.1038/s41586-022-05272-1
Citation  Krishnamurty AT, et al. (2022) LRRC15(+) myofibroblasts dictate the stromal setpoint to suppress tumour immunity. Nature 611(7934):148-154
abstractText  Recent single-cell studies of cancer in both mice and humans have identified the emergence of a myofibroblast population specifically marked by the highly restricted leucine-rich-repeat-containing protein 15 (LRRC15)(1-3). However, the molecular signals that underlie the development of LRRC15(+) cancer-associated fibroblasts (CAFs) and their direct impact on anti-tumour immunity are uncharacterized. Here in mouse models of pancreatic cancer, we provide in vivo genetic evidence that TGFbeta receptor type 2 signalling in healthy dermatopontin(+) universal fibroblasts is essential for the development of cancer-associated LRRC15(+) myofibroblasts. This axis also predominantly drives fibroblast lineage diversity in human cancers. Using newly developed Lrrc15-diphtheria toxin receptor knock-in mice to selectively deplete LRRC15(+) CAFs, we show that depletion of this population markedly reduces the total tumour fibroblast content. Moreover, the CAF composition is recalibrated towards universal fibroblasts. This relieves direct suppression of tumour-infiltrating CD8(+) T cells to enhance their effector function and augments tumour regression in response to anti-PDL1 immune checkpoint blockade. Collectively, these findings demonstrate that TGFbeta-dependent LRRC15(+) CAFs dictate the tumour-fibroblast setpoint to promote tumour growth. These cells also directly suppress CD8(+) T cell function and limit responsiveness to checkpoint blockade. Development of treatments that restore the homeostatic fibroblast setpoint by reducing the population of pro-disease LRRC15(+) myofibroblasts may improve patient survival and response to immunotherapy.
Quick Links:
 
Quick Links:
 

Expression

Publication --> Expression annotations

 

Other

1 Bio Entities

Trail: Publication

0 Expression